VIR · Biotech · Nasdaq · As of 21 Nov 2026
Vir Biotechnology, Inc. stock: filings, catalysts and timeline
Sign in to follow
AIR Score
Neutral · 60 / 100
AIR confidence
Support behind the full AIR read.
What is this? →Hide
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
The Discovery Gap
Very high
Gap confidence
How fully AIR could measure this Gap — separate from the AIR Score's confidence.
What is this? →Hide
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Five perspectives
FundamentalsWhat is this?HideToo few of the required measures on file
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideStrong
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideBalanced
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideBalanced
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Rating words, not raw numbers.
Fundamental score not available. AIR's fundamental engine is built for businesses with established revenue and cash flow; biotech financial profiles — often R&D-heavy or pre-revenue — don't yet fit the measures it requires. AIR still assesses this company on News flow, Momentum and Safety, and the missing score lowers its AIR confidence.
Discovery Gap: Very high (71/100) · Gap confidence 59/100
Discovery gap
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
This month at a glance
Evidence timeline
What changed — last 90 days
As of 17 Nov 2026The company filed results of operations for the period.
Results · 8-K filed 4 Nov →
The company filed a quarterly report for the period ending 30 September 2026.
Quarterly/annual report · 10-Q filed 4 Nov →
The company announced and priced a public offering of 15 million shares at $10.00 per share.
Major contract · 8-K filed 16 Nov →
What the company disclosed, not verified by AIR · sources link to the Evidence timeline below.
- Expected
Tue 23 Feb · expected 10-K
Last year filed 23 Feb 2026.
Fri 7 May · expected 10-Q
Last year filed 7 May 2026.
- Filed
Mon 16 Nov · 8-K
8-K · Items 1.01, 8.01 — Material agreement
Vir Biotechnology announced and priced a public offering of 15 million shares at $10.00 per share, expected to raise ~$140.4 million net proceeds (or ~$161.5 million with full option exercise). Offering closes November 16, 2026.
Mon 9 Nov · 8-K
8-K · Item 8.01 — Other events
Gap Very high · 55 → Very high · 61Progress is running ahead of attention.
Wed 4 Nov · 8-K
8-K · Item 2.02 — Results of operations
Recognition: Strong 66 → Strong 73Value: Strong 69 → Strong 73Gap Very high · 62 → Very high · 54The shares became cheaper on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
Wed 4 Nov · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Recognition: Strong 66 → Strong 73Value: Strong 69 → Strong 73Gap Very high · 62 → Very high · 54The shares became cheaper on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
Wed 28 Oct · 8-K
8-K · Item 5.02 — Director or officer change
Recognition: Strong 65 → Strong 68Gap Very high · 64 → Very high · 60The gap narrowed — attention is catching up.
Wed 14 Oct · 8-K
8-K · Items 3.02, 8.01 — Unregistered sale of shares
News flow: Balanced 53 → Balanced 56Recognition: Strong 68 → Balanced 61Gap High · 38 → Very high · 71The filings read more positively.
Market attention has faded.
Progress is running ahead of attention.
The price trend weakened.
Thu 8 Oct · 8-K
8-K · Item 8.01 — Other events
Gap High · 34 → High · 38Progress is running ahead of attention.
Thu 1 Oct · 8-K
8-K · Item 5.02 — Director or officer change
Recognition: Balanced 60 → Strong 68Gap High · 42 → High · 34The gap narrowed — attention is catching up.
The price trend strengthened.
Wed 5 Aug · 8-K
Wed 5 Aug · 10-Q
Quarterly report (10-Q), period ending 30 Jun 2026
Fri 24 Jul · 8-K
Wed 10 Jun · 8-K
Thu 28 May · 8-K
Thu 7 May · 10-Q
Quarterly report (10-Q), period ending 31 Mar 2026
Wed 6 May · 8-K
Fri 10 Apr · 8-K
Wed 4 Mar · 8-K
Mon 2 Mar · 8-K
Thu 26 Feb · 8-K
Mon 23 Feb · 8-K
Mon 23 Feb · 10-K
Annual report (10-K), FY2025
Mon 12 Jan · 8-K
Tue 16 Dec · 8-K
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.